<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515708</url>
  </required_header>
  <id_info>
    <org_study_id>15-549</org_study_id>
    <nct_id>NCT02515708</nct_id>
  </id_info>
  <brief_title>Pilot Study to Assess Safety and Feasibility of Normothermic Machine Preservation In Human Liver Transplantation</brief_title>
  <official_title>A Phase I Pilot Study to Assess Safety and Feasibility of Normothermic Machine Preservation In Human Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cristiano Quintini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Normothermic machine perfusion (NMP) preservation is a promising method to decrease the&#xD;
      complication of marginal donor livers compared to cold storage (CS). The aim of this project&#xD;
      is to assess safety and feasibility of NMP in human liver transplantation. This will be a&#xD;
      single center prospective cohort pilot study. Thirty-two livers with acceptable quality for&#xD;
      transplantation will be preserved with NMP in 2-18 hours and transplanted. The follow-up&#xD;
      period will be 6 months post-transplantation. The outcome will be compared to 100 historical&#xD;
      patients transplanted in our program in the past 5 years (liver preserved using CS) with&#xD;
      matched characteristics on age, Model for End-Stage Liver Disease (MELD) score, preservation&#xD;
      time, etc.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The shortage of donor organs leads to the use of marginal donors including donors after&#xD;
      cardiac death. Normothermic machine perfusion (NMP) preservation is a promising method to&#xD;
      decrease their high risk of complication compared to the standard cold storage (CS). The aim&#xD;
      of this project is to assess safety and feasibility of NMP in human liver transplantation.&#xD;
&#xD;
      This will be a single center prospective cohort pilot study. Thirty-two livers that have&#xD;
      acceptable quality for transplantation will be preserved with NMP in 2-18 hours after cross&#xD;
      clamp and cold flush. The liver grafts at NMP will be at physiological temperature and have&#xD;
      oxygen and nutrient supply with continuous perfusion. The transplantation and post-transplant&#xD;
      care will follow the standard of care. The follow-up period is 12 months after&#xD;
      transplantation. The primary end point will be the rate of post-transplant Early Allograft&#xD;
      Dysfunction (EAD), while the secondary end points will be: primary non function (PNF) rate, 1&#xD;
      and 6 months patient and graft survival, peak liver function tests in the first 7 days after&#xD;
      transplantation, intraoperative hepatic arterial and portal flow measurement, rate and&#xD;
      magnitude of post-reperfusion syndrome, surgical outcomes (operative time, transfusion&#xD;
      requirement etc.), rate of post-transplant kidney failure, assessment of histological&#xD;
      ischemia reperfusion (liver and bile duct), rate of vascular complications, rate of biliary&#xD;
      complications, hospital and ICU length of stay, rejection rate, infection rate, the ability&#xD;
      to predict function based on &quot;on-pump&quot; viability markers, and the incidence of adverse effect&#xD;
      (AE).&#xD;
&#xD;
      The outcome will be compared to a control group of 100 historical patients (matched with a&#xD;
      1:4 ratio) transplanted in our program in the past 10 years (liver preserved using CS).&#xD;
      Control subjects will be matched using donor and recipient age, Model for End-Stage Liver&#xD;
      Disease (MELD) score, cold ischemia time, donor risk index and presence of steatosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2016</start_date>
  <completion_date type="Actual">June 9, 2020</completion_date>
  <primary_completion_date type="Actual">June 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of Early Allograft Dysfunction post-transplantation in Normothermically Machine Perfused (NMP) livers</measure>
    <time_frame>7 days post-transplantation</time_frame>
    <description>The presence of at least one of the following at post-transplant 7 days: serum bilirubin &gt;= 10 mg/dL, international normalized ratio (INF) &gt;= 1.6; and/or aspartate aminotransferase (AST) &gt; 2000 U/L at any time in the first 7 post-transplant days (POD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>primary non-function rate</measure>
    <time_frame>in the first 10 days post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft survival</measure>
    <time_frame>6 months post-transplantation</time_frame>
    <description>The allograft will be considered lost if a patient has a liver re-transplant or in the event of patient death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak liver function tests in the first 7 days post-transplantation</measure>
    <time_frame>in the first 7 days post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative flow measurement</measure>
    <time_frame>intraoperative</time_frame>
    <description>Flows will be measured with a transit time flowmeter (VeriQ system, MediStim A/S, Oslo, Norway) after graft reperfusion. The following parameters will be recorded as per our standard practice during liver transplantation: portal venous flow, hepatic artery flow, and hepatic artery flow after temporary portal vein occlusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post reperfusion syndrome (composite)</measure>
    <time_frame>in the first 7 days post-transplantation</time_frame>
    <description>rate and magnitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgical outcomes (composite)</measure>
    <time_frame>intraoperative</time_frame>
    <description>operative time, transfusion requirement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of post-transplant kidney failure</measure>
    <time_frame>in the 1, 3, 6 ,9 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>histology of liver parenchyma</measure>
    <time_frame>On the day of transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular complications rate</measure>
    <time_frame>in the first day post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biliary complications rate</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital and ICU length of stay (composite)</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rejection rate</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>opportunistic viral infection rate</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient survival</measure>
    <time_frame>6 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>histology of bile duct</measure>
    <time_frame>On the day of transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Normothermic Liver perfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group has the liver grafts preserved using the Normothermic Liver perfusion Device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normothermic Machine Perfusion (single pump)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This group has the liver grafts preserved using a single-pump variant of the Normothermic Liver perfusion Device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Normothermic Liver perfusion Device</intervention_name>
    <description>The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.</description>
    <arm_group_label>Normothermic Liver perfusion</arm_group_label>
    <arm_group_label>Normothermic Machine Perfusion (single pump)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing primary liver transplantation&#xD;
&#xD;
          -  Age 18-75 years at the time of transplantation&#xD;
&#xD;
          -  Willingness and ability to comply with the study procedures&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
          -  For patients with hepatocellular carcinoma as indication for Orthoptic Liver&#xD;
             Transplantation (OLT), tumor must be within Milan Criteria or down-staged to Milan&#xD;
             Criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Recipient Exclusion Criteria:&#xD;
&#xD;
          -  History of prior solid organ transplantation&#xD;
&#xD;
          -  Patient on a respiratory and/or cardiocirculatory support at the time of transplant&#xD;
&#xD;
          -  MELD score &gt;35&#xD;
&#xD;
          -  HIV positive patient&#xD;
&#xD;
          -  Patient with current severe systemic infection&#xD;
&#xD;
          -  Multiorgan transplant&#xD;
&#xD;
        Donor Exclusion Criteria:&#xD;
&#xD;
          -  Donor age &lt;14 or &gt;70 years&#xD;
&#xD;
          -  Liver steatosis (on visual estimate or on liver biopsy) &gt; 30%&#xD;
&#xD;
          -  Donors with Grade 2-3 traumatic liver laceration&#xD;
&#xD;
          -  Partial grafts (living donors and split liver donors)&#xD;
&#xD;
          -  Liver in which the investigator is unwilling or unable (for logistical reasons) to&#xD;
             perform normothermic machine perfusion (NMP) preservation&#xD;
&#xD;
          -  Inability to NMP perfuse the liver within 4 hours after cross clamp&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristiano Quintini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 30, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Cristiano Quintini</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 11, 2021</submitted>
    <returned>April 5, 2021</returned>
    <submitted>September 30, 2021</submitted>
    <returned>October 28, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

